Zhejiang Bio-Aibo Medical Laboratory was established on April 29, 2015, and is located at Block D, Building 4, No. 63 Jiuhuan Road, Jianggan District, Hangzhou. It is a third-party medical laboratory engaged in genetic diagnostic engineering and is a state-owned enterprise controlled by Tsinghua Holdings. It is affiliated with Beijing Bio-Aibo Medical Laboratory Co., Ltd., which is a third-party independent medical laboratory wholly established by CapitalBio Group.
Zhejiang Bio-Aibo Medical Laboratory has successfully applied to become a Zhejiang Provincial Demonstration Center for the Application of Gene Testing Technology. Based on biochip sequencing technology, it adheres to CapitalBio's excellent concept of "government-industry-academia-research-application" and cooperates with the local government to provide the public with testing services such as early warning, prevention, and personalized diagnosis and treatment of major diseases.
Beijing Bio-Aibo Medical Laboratory is located in Yizhuang Biomedical Park, Beijing Economic-Technological Development Area, and was established on November 19, 2012. It is a third-party independent medical laboratory wholly established by CapitalBio Corporation and the Beijing National Engineering Research Center for Biochips (hereinafter referred to as "CapitalBio").
Beijing Bio-Aibo Medical Laboratory is an institution in China with all six certificates for clinical application of genetic testing, including: qualification as a pilot unit for personalized medicine testing; qualification as a pilot unit for clinical application of high-throughput sequencing technology in genetic disease diagnosis, prenatal screening and diagnosis, and preimplantation embryo genetic diagnosis; qualification as a clinical pilot unit for high-throughput gene sequencing technology in tumor diagnosis and treatment projects; as well as medical device registration certificates for a series of genetic testing products such as CapitalBio Group's BioelectronSeq 4000 high-throughput gene sequencer and fetal chromosome aneuploidy (T21, T18, T13) detection kits.
At present, Bio-Aibo Testing has developed into a high-end and distinctive personalized molecular diagnostics center. Bio-Aibo Testing has multiple laboratories, including molecular and cytogenetics, tumor molecular testing, cardiovascular and cerebrovascular disease molecular testing, and infectious disease molecular testing, and mainly provides the following testing services: genetic testing for hereditary deafness, genetic testing for Down syndrome, tandem mass spectrometry screening for neonatal inherited metabolic diseases, chromosome karyotype analysis and FISH testing, chromosome abnormality testing, thalassemia testing, other single-gene disease testing, hereditary tumor genetic testing, tumor-related virus genetic testing, plasma miRNA marker testing, breast cancer prognostic genetic testing, leukemia fusion gene testing, multiple myeloma genetic testing, tumor personalized medication genetic testing, cardiovascular and cerebrovascular disease personalized medication genetic testing, human papillomavirus (HPV) typing testing, hepatitis molecular diagnosis, mycobacterium testing, other infectious disease testing, and other projects.
In order to better benefit the public through science and technology, Bio-Aibo Testing is based in Beijing and radiates across the country. It wholly owns Chengdu Bio-Aibo Independent Medical Laboratory, Zhengzhou Bio-Aibo Medical Laboratory, Changchun Bio-Aibo Medical Laboratory, Guangdong Bio-Aibo Medical Laboratory, Zhejiang Bio-Aibo Medical Laboratory, Shanghai Bio-Aibo Medical Laboratory, Hunan Bio-Aibo Medical Laboratory, Suzhou Bio-Aibo Medical Laboratory, Qingdao Bio-Aibo Medical Laboratory, Fujian Bio-Aibo Medical Laboratory, Shandong Bio-Aibo Medical Laboratory, Xinjiang Bio-Aibo Medical Laboratory, etc., and will also invest in and build a considerable number of medical laboratories across the country, forming a nationwide group development model for third-party medical testing.
The ability of Beijing Bio-Aibo Medical Laboratory to achieve such development in just a few years cannot be separated from the support of its strong group background—CapitalBio Group.
On September 30, 2000, CapitalBio Corporation and the Beijing National Engineering Research Center for Biochips (abbreviated as CapitalBio) were registered and established with the care and support of leaders from the State Council, the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Education, the Ministry of Health, and Beijing Municipality, relying on Tsinghua University and jointly with Huazhong University of Science and Technology, the Chinese Academy of Medical Sciences, and the Academy of Military Medical Sciences. The registered capital is RMB 376.5 million, and it has a 65,000-square-meter base for R&D, production, operations, and services. The group president, Cheng Jing, is an academician of the Chinese Academy of Engineering and an academician of the International Eurasian Academy of Sciences. He is a returnee talent recruited overseas under Tsinghua University's "Hundred Talents Program" and currently serves as a professor and doctoral supervisor in the Department of Biomedical Engineering, School of Medicine and the Biology Research Center of the Department of Medicine at Tsinghua University, and as director of the Beijing National Engineering Research Center for Biochips. He has received the National Science Fund for Distinguished Young Scholars, is a specially appointed professor under the Ministry of Education's "Yangtze River Scholars Program," and was selected for the Organization Department of the CPC Central Committee's "*."
Against this background, CapitalBio Group has grown rapidly in various business fields and in 2015 formed a group operating structure encompassing five major research institutes and five major subsidiaries. Among them, the five major research institutes include the Institute of Health Science, the Institute of Translational Medicine, the Institute of Engineering Translation, the Institute of Translational Bioinformatics, and the Institute of Health Technology. The five major subsidiaries include Beijing Bio-Aibo Medical Laboratory Co., Ltd. (Bio-Aibo Testing), Beijing CapitalBio Technology Co., Ltd. (CapitalBio Technology), Bio-Aibo Yihe Health Science and Technology (Beijing) Co., Ltd. (Bio-Aibo Yihe), Dongguan Bio-Aibo Muhua Gene Technology Co., Ltd. (Bio-Aibo Muhua), and Chengdu Bio-Aibo Xinjing Medical Technology Co., Ltd. (Bio-Aibo Xinjing). Among them, CapitalBio Technology, relying on Tsinghua University and CapitalBio Group, is based on next-generation biological detection technologies (chip, sequencing, multiplex PCR, mass spectrometry, cell sorting, and other technologies) and provides instruments and equipment, supporting reagents and consumables, scientific research service outsourcing, and overall laboratory solutions to the fields of life science research, medical testing, molecular breeding, agriculture, forestry and animal husbandry, new drug R&D, and food safety at home and abroad; Bio-Aibo Yihe is committed to "building an individual-centered comprehensive health management system," and its products and services cover disease prediction, prevention, early diagnosis, health testing, health conditioning, constitution intervention, sports rehabilitation, home-based elderly care, and other fields. It is the pioneer and practitioner of the scientific and personalized "whole-person, whole-process" health management concept; Bio-Aibo Muhua is a high-tech enterprise specializing in new-generation high-throughput sequencing, bioinformatics analysis, translational medicine research and application, and scientific research cooperation; and Bio-Aibo Xinjing, as an important part of CapitalBio Group's industrialization strategy, focuses on the fields of cell and immune diagnosis, is committed to providing patients with rapid and precise disease diagnostic products, and continuously explores the huge potential brought by emerging fields such as circulating tumor cell detection.
Today, CapitalBio, which leads in application fields such as "life science research, health evaluation and clinical diagnosis, and biological (including food) safety testing," has begun to continuously provide high-quality life science and technology services and overall industry application solutions to a large number of customers and partners at home and abroad. Its series of products and services developed and produced have been exported to more than 30 countries and regions in North America, Europe, Asia, and elsewhere. Among them, diagnostic biochips and related instrument products have entered hundreds of hospitals in the United Kingdom, Germany, Sweden, Italy, Spain, Austria, Switzerland, Portugal, Finland, Denmark, Japan, Singapore, and other countries.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows